SCHEMBL6543659

SCHEMBL6543659

CCOC(=O)C(C)CN1CCCCC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 2/20 0.51
ADRA2B P18089 2/20 0.51
DRD3 P35462 2/20 0.51
SIGMAR1 Q99720 2/20 0.51
HRH3 Q9Y5N1 2/20 0.51
ALDH1A1 P00352 5/20 0.50
LMNA P02545 1/20 0.50
CYP2D6 P10635 1/20 0.49
ADRA2C P18825 1/20 0.49
CHRM3 P20309 1/20 0.49
OPRD1 P41143 1/20 0.49
KCNH2 Q12809 1/20 0.49
CYP3A4 P08684 1/20 0.44
CYP2C19 P33261 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
GAA P10253 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25322115 0.98 CHRM2 (0.49) CHRM2ADRA2BDRD3SIGMAR1HRH3
SCHEMBL9774559 0.83 CHRM2 (0.49) CHRM2ADRA2BDRD3SIGMAR1HRH3
SCHEMBL1857702 0.82 CYP3A4 (0.42) CHRM2ADRA2BDRD3SIGMAR1HRH3
SCHEMBL16267250 0.82 PADI1 (0.47) CHRM2ADRA2BDRD3SIGMAR1HRH3
SCHEMBL11668730 0.82 ALDH1A1 (0.62) ALDH1A1LMNACYP3A4CYP2C19L3MBTL1
SCHEMBL64561 0.81 CHRM2 (0.46) CHRM2ADRA2BDRD3SIGMAR1HRH3
SCHEMBL16267349 0.80 CYP3A4 (0.38) CHRM2ADRA2BDRD3SIGMAR1HRH3
SCHEMBL1863187 0.80 CYP3A4 (0.43) CHRM2ADRA2BDRD3SIGMAR1HRH3
SCHEMBL16265608 0.80 CYP3A4 (0.43) CHRM2ADRA2BDRD3SIGMAR1HRH3
SCHEMBL2959602 0.79 KMT2A (0.43) CHRM2ADRA2BDRD3SIGMAR1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1259475-A4 TRANSITION METAL-CATALYZED PROCESS FOR ADDITION OF AMINES TO CARBON-CARBON DOUBLE BONDS UNIV YALE (US) 2004-08-18 EP disclosed
EP-1259475-A1 TRANSITION METAL-CATALYZED PROCESS FOR ADDITION OF AMINES TO CARBON-CARBON DOUBLE BONDS YALE UNIVERSITY (US) 2002-11-27 EP disclosed
US-6384282-B2 CATALYST IS REACTION PRODUCT OF GROUP 8 METAL AND LIGAND YALE UNIVERSITY 2002-05-07 US disclosed
US-20020016509-A1 Transition metal-catalyzed process for addition of amines to carbon-carbon double bonds YALE UNIVERSITY 2002-02-07 US disclosed
WO-2001064620-A1 TRANSITION METAL-CATALYZED PROCESS FOR ADDITION OF AMINES TO CARBON-CARBON DOUBLE BONDS YALE UNIVERSITY (US) 2001-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020016509-A1 Transition metal-catalyzed process for addition of amines to carbon-carbon double bonds COASY, CMA1, ATIC CHRM2 578/4885ADRA2B 865/4885DRD3 714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.